27 October 2022 | Other

Merck CEO will take charge of the company’s chairman

On Wednesday, the company Merck & Co announced that Ken Frazier leaves the post of chairman. He will be replaced by Chief Executive Officer Rob Davis, who has taken on extra responsibilities on December 1.

Frazier joined the company nearly 30 years ago, and over the years, he was helping the company to stay among the leaders in the drug production field.

He was steering the company during the difficult lawsuit related to the painkiller Vioxx, which was withdrawn from the market. He also played a pivotal role in the acquisition of US drug product manufacturer Schering-Plough. In 2009 the company received the possibility to sell the drug Keytruda. Then, this drug became Merck's best-selling product. 



Company MarketCheese
Period: 01.11.2026 Expectation: 6300 pips
Buy Tesla stock with $430 in sight
Today at 08:51 AM 4
Period: 20.11.2026 Expectation: 1200 pips
Invest in AUDUSD ahead of Fed and RBA meetings
Today at 06:56 AM 5
Period: 19.11.2026 Expectation: 9435 pips
Buying silver up to $67.00
Yesterday at 10:16 AM 19
Gold buy
Period: 31.10.2026 Expectation: 200 pips
Go long on gold with $4,375 in mind
Yesterday at 06:40 AM 26
Period: 16.11.2026 Expectation: 5700 pips
Invest in GBPUSD up to 1.38700
16 October 2026 76
Period: 31.10.2026 Expectation: 1300 pips
Selling AUDCAD from 0.9890
16 October 2026 84
Go to forecasts